The harmful and anti-competitive business practices that PBMs thrive on are made possible by the industry’s secrecy and lack of transparency. Plan sponsors and beneficiaries should be given more information about how their insurance plans are managed and what rates are negotiated. Pharmacies should be allowed, and even encouraged, to point customers to lower-cost alternatives […]
The news coverage about pre-existing conditions leave out a lot. Popular media outlets focus on government operated public plans such as the Affordable Care Act (ACA) health insurance exchange options, or Medicare, or Medicaid. Often neglected are the employer-provided health benefit plans and short-term health insurance plans. Many health care benefit plans are available for […]
Today President Trump signed a package of measures that includes the provisions of The Synthetics Trafficking and Overdose Prevention (STOP) Act. This marks a critical step toward codifying critical changes to the U.S. Postal Service’s protocols that will greatly assist law enforcement and security agencies. Under the current framework the U.S. Postal Service’s network has […]
For the past 60 years the federal government has been advising consumers on how they can avoid heart attacks and strokes. The federal government’s Dietary Guidelines Advisory Committee took advice from well-known food scientists even though the advising scientists often held conflicting conclusions. The Advisory Committee’s advice to consumers changed slowly and has often been […]
The 5th generation wireless (5G) service being deployed today promises to deliver super-fast low latency broadband to phones or homes. Despite some highly promising applications, health care is underrepresented in its use of broadband for competitive and policy reasons but not for technical reasons. The usual pathway for your use of 5G would be via […]
Consumers have a love-hate relationship with prescription drugs. We love the wonderful new drugs that treat and sometimes cure conditions that were once life-threatening, but we hate the sometimes-unaffordable prices of the latest drugs. Consumers who have prescription insurance coverage are somewhat insulated from the full price of drugs, but insurers and pharmacy benefit managers […]
A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.
What if there was a way to simultaneously reduce the stunning levels of health care fraud in the United States while also combating the opioid crisis ravaging our communities? Well, there is. To read this op-ed, please visit the Morning Consult.
Replacing the current Medicare card with a high-tech “smart card” could help prevent billions of dollars in fraud while reducing medical errors and saving lives. To Read this op-ed, visit Real Clear Health.
Lowering the consumer price for a drug is in the public interest, provided that its sales margin recovers its development cost. Pharmaceuticals do not spontaneously emerge like weeds in a field. They are complex chemical or biological agents that are painstakingly designed and extensively tested for safety and efficacy. That said, there are steps worth […]